Skip to main content
. 2019 Oct 23;9:15202. doi: 10.1038/s41598-019-50917-3

Figure 5.

Figure 5

Mit-A - a bona fide anti-CSC target. (A,C,E) HT29, HCT116 and KM12 cells, respectively, were plated in 96 well ultra-low attachment plates and treated with indicated doses of Mit-A for 5 consecutive days to allow the formation of spheres. Images were taken through an inverted microscope and area of spheres was counted (B,D,F, respectively) by using ImageJ software. (G) Area of the spheres treated with different anti-cancer drugs, Carboplatin, Oxaliplatin, 5-FU or Mit-A. (H,I) Total RNA was isolated from HT29 (H) and HCT116 (I) spheres treated with vehicle and Mit-A with indicated dose, and OCT-4 gene expression analyzed by qPCR. Each data point indicates mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001. A representative of two experiments is shown.